Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE